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ABSTRACT: Antibody-dependent cellular cytotoxicity (ADCC) is a cytolytic mechanism that
can elicit in vivo antitumor eﬀects and can play a signiﬁcant role in the eﬃcacy of antibody
treatments for cancer. Here, we prepared cetuximab, panitumumab, and rituximab containing
gold nanoparticles and investigated their ability to produce an ADCC eﬀect in vivo. Cetuximab
treatment of EGFR-expressing H1975 tumor xenografts showed signiﬁcant tumor regression
due to the ADCC activity of the antibody in vivo, while the control antibody, panitumumab,
did not. However, all three antibody containing nanoparticles are not able to suppress tumor
growth in the same in vivo mouse model. The antibody containing nanoparticles localized in
the tumors and did not suppress the immune function of the animals, so the lack of tumor
growth suppression of the cetuximab containing nanoparticle suggests that immobilizing
antibodies onto a nanoparticle signiﬁcantly decreases the ability of the antibody to promote an
ADCC response.
■ INTRODUCTION
A number of targeted nanoparticles have now been investigated
in human clinical trials.1,2 At this time, there is no clinical
example of a full antibody targeted nanoparticle. Since
immunotherapies are ﬁnding increased importance in cancer,
the use of a full antibody targeted nanoparticle could be
interesting. This type of therapeutic could potentially elicit
immunotherapeutic functions such as antibody-dependent
cellular cytotoxicity (ADCC) and complement dependent
cytotoxicity (CDC) in addition to targeting the nanoparticles
to cancer cell surface receptors and blocking cell signaling from
those receptors. While antibody fragments can elicit the latter
two functions, they do not stimulate immunotherapeutic
pathways.
Numerous preclinical studies utilize full antibody targeted
nanoparticles. However, only one investigation has speciﬁcally
explored the possibility of stimulating an ADCC response.3
Rituximab is an IgG1 antibody that binds to the CD20
receptor, and rituximab containing lipid nanoparticles were
investigated both in vitro and in vivo for their ability to elicit
ADCC. Rituximab nanoparticles exhibited ADCC cell lysis in
vitro, but the observed in vivo therapeutic eﬃcacy of the
antibody−lipid conjugates could not be ascribed to ADCC
function.3
Natural killer (NK) cell based immunotherapies have shown
considerable potential for cancer therapy in the clinic.4,5 ADCC
is an immune mechanism dependent on the activity of CD56dim
CD16+ NK cells. Transgenic mouse models deﬁcient in the
CD16 receptor, also known as the activating Fcγ (FcγRIIIa/
CD16) receptor, are unable to inhibit tumor growth in the
presence of IgG1 antibodies that primarily work by inducing an
ADCC response.6 Various types of peripheral blood mono-
nuclear cells (PBMCs) have been studied for their antitumor
ADCC activities in vitro, and NK cells have been found to
induce the most potent ADCC response.7
Cetuximab and panitumumab are two antibodies that
speciﬁcally target the epidermal growth factor receptor I
(EGFRI) and possess similar EGFR binding aﬃnities.8,9 In
contrast to cetuximab, panitumumab is not able to elicit an
ADCC response.10 Here, we address the question as to whether
full antibodies that are displayed on the surface of nanoparticles
can elicit an ADCC response in vivo. In order to observe
antitumor eﬀects that would be speciﬁc to an ADCC response,
we selected a lung cancer cell line (H1975) that does not show
any in vitro antiproliferative eﬀects upon treatment with either
cetuximab or panitumumab. Thus, any antitumor behavior
observed in vivo can be ascribed to an ADCC function
(positive for cetuximab and negative for panitumumab). Since
gold nanoparticles will not have antitumor eﬀects, antibody
containing gold nanoparticles were prepared using cetuximab,
panitumumab, and rituximab (negative control) and inves-
tigated in vivo with xenografts of the EGFR-expressing H1975
lung cancer cell line in athymic nude mice. While cetuximab
alone reveals signiﬁcant ADCC dependent antitumor behavior,
the lack of antitumor function with the cetuximab containing
gold nanoparticles shows that the ADCC function from
antibody containing nanoparticles maybe be diﬃcult to achieve
in vivo.
■ RESULTS AND DISCUSSION
Assembly of Antibody Containing Gold Nanoparticle.
The assembly of the antibody containing gold nanoparticles
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was accomplished as follows. Conjugates of polyethylene glycol
(PEG) and cetuximab, panitumumab, and rituximab were
prepared by antibody reaction with NHS−PEG−OPSS (reacts
with amine groups of antibodies to yield antibody−PEG
conjugates through amide bond formation (Scheme 1)). High-
pressure liquid-phase chromatography (HPLC) puriﬁed anti-
body−PEG conjugates were analyzed by MALDI-TOF-MS and
conﬁrmed to be mono-PEGylated. 50 nm gold nanoparticles
(AuNPs) were then functionalized with the mono-PEGylated
antibody−PEG conjugates and mPEG-SH (Scheme 1) and
were analyzed for their average hydrodynamic diameter and
surface charge (Table 1). The quantitative number of
antibodies per nanoparticle was obtained using two diﬀerent
methods. The results from the two were consistent with each
other (Supporting Information, Table S1), and the mean values
obtained from the two methods are presented in Table 1.
PEGylated AuNPs containing approximately 15−20 antibodies
per particle have negative ζ potential values and are stable in
deionized water and saline solutions.
In Vitro Cytotoxicity of Antibodies and Antibody-
Functionalized Gold Nanoparticles. The H1975 cell line
harbors a double mutation in the kinase domain of EGFR that
makes these cells insensitive to treatments with tyrosine kinase
inhibitors (TKIs). Also, EGFR speciﬁc monoclonal antibodies
do not produce antiproliferative eﬀects with the H1975 cells in
vitro.11 The in vivo antitumor eﬀects observed with cetuximab
Scheme 1. Assembly of Antibody Containing Gold Nanoparticlesa
a(A) Antibodies ﬁrst reacted with the NHS−PEG−OPSS and then puriﬁed. (B) In a second step, the antibody conjugates were then combined with
mPEG-SH and assembled onto the surface of the gold nanoparticles.
Table 1. Properties of Antibody Containing AuNPs
sample size (nm) by DLSa size (nm) by NTAb ζ potential (mV)c no. of antibodies on surface
cetuximab−AuNPs 79.5 ± 4 72.6 ± 0.4 −18.7 ± 1 19 ± 6
panitumumab−AuNPs 72.8 ± 1.9 74.8 ± 1.6 −19.2 ± 2.1 20 ± 5
rituximab−AuNPs 82.5 ± 5.5 73.2 ± 1.3 −20.5 ± 1.7 17 ± 3
mPEG−AuNPs 64.1 ± 9.5 72.3 ± 0.9 −19.4 ± 4.3 0
aDLS (Dynamic Light Scattering), measured in phosphate buﬀered saline (PBS). bNTA (Nanoparticle Tracking Analysis), measured in deionized
water. cMeasured in 1 mM KCl solution in deionized water.
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are thought to be associated with the ADCC activity of the
antibody. Here, the antiproliferative eﬀects of the antibodies
cetuximab, panitumumab, and rituximab and the corresponding
antibody containing AuNPs were investigated with the EGFR-
TKI resistant H1975 lung cancer cell line via a cell viability
assay. The H1975 cells remained viable in the presence of all
antibodies and antibody containing AuNPs (Supporting
Information, Figure S1) 72 h post-treatment. The results are
consistent with previous reports that show no in vitro cell death
upon exposure of H1975 lung cancer cells to cetuximab or
panitumumab10 and reveal that multiple antibodies on the
surface of the AuNPs also do not produce any antiproliferative
eﬀects in vitro.
Figure 1. Eﬀects of antibody treatment on H1975 xenograft tumors in nude mice. Mice were treated with cetuximab (circles), panitumumab
(squares), or saline (triangles) as a negative control. Arrows indicate the days treatment occurred.
Figure 2. H1975 xenograft tumor growth in mice treated with antibody containing AuNPs. Nonantibody containing AuNPs, rituximab containing
AuNPs, and saline were used as negative controls. Arrows indicate the days treatment occurred.
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Antitumor Eﬀects of Antibodies and Antibody
Containing AuNPs. To investigate the role of ADCC in
vivo, mice bearing established H1975 xenograft tumors were
dosed twice a week for 2 weeks, and tumor growth was
measured over a period of 2 months. Cetuximab treated mice
showed signiﬁcant tumor regression, while panitumumab
treated mice did not (Figure 1). Thus, cetuximab treatments
inhibit in vivo H1975 tumor growth, and these results are
consistent with literature reports.
Antibody containing AuNPs were investigated for their
antitumor activities in nude mice bearing H1975 tumor
xenografts in order to compare to the results of treatments
with the antibodies alone. The data illustrated in Figure 2 show
that neither the cetuximab nor panitumumab containing
AuNPs produced an antitumor eﬀect in vivo (compared to
saline, rituximab containing AuNPs, and AuNPs with no
antibody (mPEG AuNP)). These results show that attaching
the antibody to the surface of the AuNPs abolished cetuximab’s
ADCC activity in vivo.
Lack of ADCC with Cetuximab Containing AuNPs Is
Not Due to Loss of Tumor Accumulation or Presence of
Immune Cells. The strong tumor regression observed in
cetuximab treated mice (Figure 1) is attributed to the ADCC
activity of cetuximab. As expected, no antitumor eﬀects are
observed with panitumumab, which does not elicit an ADCC
eﬀect. This diﬀerence in the antitumor eﬀect between the two
antibodies was completely abolished when they were attached
to the AuNPs (Figure 2). Unfortunately, we were not able to
construct an in vitro model system for testing the ADCC
activity of cetuximab or panitumumab. However, we were able
to do so for trastuzumab using the BT474M1 cell line and
immortalized NK cells (Supporting Information, Materials and
Methods). These model data show that trastuzumab and
trastuzumab AuNPs give an in vitro ADCC response
(Supporting Information, Figure S2). Since we used the same
conjugation chemistry with cetuximab and panitumumab as
with trastuzumab, we assume that at least some fraction of the
antibodies displayed on the surfaces of the nanoparticles are
able to bind to their cancer cell surface receptors and stimulate
an ADCC response in vitro. Thus, in order to better
understand the factors that cause the in vivo loss in antitumor
eﬀects for the cetuximab that is contained on the AuNPs, we
must ﬁrst prove that the AuNPs are in fact reaching the tumors
and that these tumors possess immune cells.
AuNPs in tissue can be visualized by silver staining and
imaging by light microscopy. Images of silver stained tissues
harvested from mice treated with antibody containing AuNPs
(Supporting Information, Figure S3) show the presence of
AuNPs in all treated tumor tissues, as well as in liver, spleen,
and small amounts in kidney (nontumor organs were imaged to
conﬁrm that the AuNPs were reaching all organs expected with
NPs). No staining was evident for tissues from mice treated
with saline (negative control). Thus, the AuNPs are localizing
to the tumors in these mice. The presence of immune cells
within the tumor tissue was investigated by staining for CD45
(pan-leukocyte) and CD11b (NK) immune cell markers. In
comparison to saline treated tumors, no signiﬁcant diﬀerence in
the presence of immune cells in tumor sections was found for
antibody or antibody containing AuNP treated mice (Support-
ing Information, Figures S4 and S5).
Lack of ADCC with Cetuximab Containing AuNPs Is
Due to Loss of ADCC Function. The in vivo antitumor data
shown here reveal that an antibody that can elicit an ADCC
eﬀect when used alone loses this function when it is conjugated
onto a nanoparticle. Cetuximab injected at 9.3 mg/kg showed
signiﬁcant tumor regression due to an ADCC eﬀect, while
cetuximab containing AuNPs dosed at 0.44 mg of antibody/kg
did not show any antitumor eﬀects. It should be noted that
cetuximab maintains antitumor activities in nude mice over the
range of 0.4−40 mg/kg.12
The mice dosed with 0.44 mg/kg of cetuximab containing
AuNPs (0.299 nmoles of gold/gram of body weight) showed
signiﬁcant accumulation of AuNPs in dermis, spleen, liver, and
kidney, as revealed by sharp changes in skin color and silver
staining of tissues from treated mice. Similar deposition of
targeted and nontargeted PEGylated AuNPs in mouse dermis
and lymph nodes was previously observed when studied at a
much lower dose of AuNPs per mouse.13 Most importantly, the
AuNPs also traﬃcked to the tumors (Supporting Information,
Figure S3). Thus, the lack of antitumor eﬀects with the
cetuximab containing AuNPs is not because the NPs did not
reach the tumor.
It has been argued that introducing NPs into animals can
modify their immune response via secretion of anti- or
proinﬂammatory cytokines, which in turn has an impact on
immune cell surveillance in tumor tissues.14−16 Here, the
presence of immune cells in tumor tissues was studied using
antibodies against CD45 (for all leukocytes) and CD11b (for
mouse NK cells). Immune cell surveillance in the tumors used
here was not signiﬁcantly diﬀerent regardless of treatment
(Supporting Information, Figures S4 and S5). CD45 and
CD11b labeled immune cells were abundant in H1975 tumor
xenografts, indicating that the inability of the cetuximab
containing AuNPs to show an antitumor eﬀect in vivo was
not due to a suppression of the animal’s immune response.
The results presented here lead to the conclusion that
covalent immobilization of an antibody on a nanoparticle
surface can eliminate the ADCC function of the antibody. Here,
we conjugated the antibody to PEG via reactions with amines
on the antibody. Because of the presence of several amines on
the antibody, the conjugation of the PEG component will occur
at various sites on the antibody. The antibody−PEG conjugates
were puriﬁed by HPLC to obtain a mono-PEGylated fraction
for attachment to the nanoparticle surface. However, the
orientation and distribution of antibodies on the nanoparticle
surface, such as whether the Fc region is accessible to immune
cell binding may play an important role in eliminating the
ADCC eﬀects in vivo. Results from a model in vitro system
suggest that at least a fraction of the antibodies that are
contained on the surfaces of the gold nanoparticles can bind to
the appropriate cancer cell surface receptor and stimulate an in
vitro ADCC response. Thus, at this time, the mechanistic origin
of the in vivo loss in ADCC with nanoparticle containing
antibodies remains unknown. The ability to perform site-
speciﬁc conjugation to the antibody like what is presently done
with antibody−drug conjugates17 may help resolve some of
these issues.
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